Diversified Trust Co Has $386,000 Stock Holdings in Insulet Corporation $PODD

Diversified Trust Co reduced its position in shares of Insulet Corporation (NASDAQ:PODD) by 77.3% during the 1st quarter, HoldingsChannel.com reports. The firm owned 1,841 shares of the medical instruments supplier’s stock after selling 6,261 shares during the quarter. Diversified Trust Co’s holdings in Insulet were worth $386,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp boosted its position in Insulet by 2.1% during the 4th quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock worth $896,916,000 after buying an additional 65,317 shares during the period. Geode Capital Management LLC increased its position in Insulet by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock valued at $568,274,000 after acquiring an additional 41,019 shares during the period. Invesco Ltd. increased its position in Insulet by 10.5% in the 4th quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock valued at $420,835,000 after acquiring an additional 141,167 shares during the period. Norges Bank bought a new position in shares of Insulet during the fourth quarter valued at $300,794,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Insulet by 3.8% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 806,119 shares of the medical instruments supplier’s stock valued at $229,131,000 after acquiring an additional 29,690 shares during the last quarter.

Analysts Set New Price Targets

Several brokerages recently weighed in on PODD. Weiss Ratings cut shares of Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday. Citigroup lowered their target price on Insulet from $175.00 to $165.00 and set a “neutral” rating for the company in a research report on Thursday, May 28th. Raymond James Financial set a $216.00 price target on Insulet in a research report on Monday, June 8th. William Blair started coverage on Insulet in a research note on Wednesday, May 20th. They issued an “outperform” rating for the company. Finally, Canaccord Genuity Group lowered their price objective on Insulet from $435.00 to $249.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Twenty-two analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Insulet has an average rating of “Moderate Buy” and an average target price of $238.67.

Insider Activity at Insulet

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the purchase, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.36% of the stock is currently owned by company insiders.

Insulet Stock Up 2.9%

Insulet stock opened at $158.25 on Friday. Insulet Corporation has a 1-year low of $138.79 and a 1-year high of $354.88. The firm has a market capitalization of $10.96 billion, a price-to-earnings ratio of 36.80, a price-to-earnings-growth ratio of 1.07 and a beta of 1.13. The firm’s fifty day moving average price is $159.09 and its two-hundred day moving average price is $220.64. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. During the same period in the previous year, the firm posted $1.02 earnings per share. The firm’s revenue for the quarter was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities research analysts predict that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.